Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors

详细信息    查看全文

• 作者：Iris Contreras-Hernández (1)
  Joaquín F Mould-Quevedo (1)
  Rubén Torres-González (2)
  María Victoria Goycochea-Robles (3)
  Lizette Reyna Pacheco-Domínguez (1)
  Sergio Sánchez-García (4)
  Juan Manuel Mejía-Aranguré (5)
  Juan Gardu?o-Espinosa (1)
  
• 刊名：Cost Effectiveness and Resource Allocation
• 出版年：2008
• 出版时间：December 2008
• 年：2008
• 卷：6
• 期：1
• 全文大小：1107KB
• 参考文献：1. Rousseau JC, Delmas PD: Biological markers in osteoarthritis. / Nat Clin Pract Rheumatol 2007, 3:346-56. CrossRef
  2. Murray CJL, Lopez AD: The global burden of disease. Geneva: World Health Organization 1997.
  3. Torres-Gonzàlez R, Pèrez-Correa J, Gaitàn-Morales L: Rating Scale for osteoarthritis knee assesment. / Cir Cir 2006,74(5):343-49.
  4. Stitik TP, Alshuler E, Foye PM: Pharmacotherapy of osteoarthritis. / Am J Phys Med Rehabil 2006,85(Suppl):S15-S28. CrossRef
  5. Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, / et al.: Meta-analysis: chondroitin for osteoarthritis of the knee or hip. / Ann Intern Med 2007, 146:580-90.
  6. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophi JM: Association of selective and conventional nonsteroidal anti-inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. / Am J Epidemiol 2006, 164:881-89. CrossRef
  7. Graham DJ: COX-2 inhibitors, other NSAIDs, and cardiovascular risk. The seduction of common sense. / JAMA 2006, 296:1653-656. CrossRef
  8. Borer JS, Simon LS: Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. / Arthritis Res Ther 2005,7(suppl 4):S14-S22. CrossRef
  9. Zhang J, Ding EL, Song Y: Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. Meta-analysis of randomized trials. / JAMA 2006, 296:1619-632. CrossRef
  10. Tanne JH: Reports cite cardiovascular risks of COX2 inhibitors and NSAIDs. / BMJ 2006, 333:565. CrossRef
  11. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G: Acetaminophen for osteoarthritis. / Cochrane Database Syst Rev (2):CD004257.
  12. Research Highlights: Potential anti-inflammatory role of paracetamol in knee OA. / Nat Clin Pract Rheumatl 2007, 3:67.
  13. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. / BMJ 2006, 332:1302. CrossRef
  14. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ: Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. / Arch Intern Med 2000, 160:2998-003. CrossRef
  15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, / et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. / N Engl J Med 2000, 343:1520-. 2p following 1528 CrossRef
  16. Goldstein JL, Eisen GM, Stenson W, Agrwal N, Bello AE, Fort JG, / et al.: Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2-specific inhibitor, compared with conventional NSAIDs: the SUCCESS I trial. / Gastroenterology 2001, 120:A105.
  17. Arthritis Pain Society: Guidelines for the management of pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. [http://www.ampainsoc.org/pub/arthritis.htm] 2002.
  18. MacLean CH, Knight K, Paulus H, / et al.: Costs attributable to osteoarthritis. / J Rheumatol 1998, 25:2213-218.
  19. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C, Community Hypertension and Arthritis Project Study Team: The economic burden associates with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. / Ann Rheum Dis 2004, 63:395-01. CrossRef
  20. Leardini G, Salaffi F, Caporali R, Canesi B, Rovati L, Montanelli R, Italian Group for Study of the Costs of Arthritis: Direct and indirect cost of osteoarthritis of the knee. / Clin Exp Rheumatol 2004, 22:699-06.
  21. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. / N Engl J Med 2002, 347:2104-110. CrossRef
  22. Amui-Sutton A, Irigoyen-Coria A, Gómez-Clavelina FJ, Fernández-Ortega MA: Polìticas sociales contra la pobreza y en favor de la salud en México. / Rev Med Inst Mex Seguro Soc 2006, 44:455-60.
  23. Constantino-Casas P, Torres-Arreola LP, Posadas-García JL, Nevárez-Sida A, García-Contreras F: Prescripción de certificados de incapacidad temporal en el IMSS. Perspectiva desde la economía de la salud. / Rev Med Inst Mex Seguro Soc 2007, 45:89-6.
  24. Mu?oz-Hernandez O: Programas integrados de salud (PREVENIMSS). / Rev Med Inst Mex Seguro Soc 2006,44(suppl 1):S1-S2.
  25. Vladislavouvna-Douboba S, Torres-Arreola LP, Reyes-Morales H: Analgésicos antiinflamatorios no esteroideos en la terapia del dolor. Orientación para su uso en el primer nivel de atención. / Rev Med Inst Mex Seguro Soc 2006, 44:565-72.
  26. Mu?oz-Hernández O, Gardu?o-Espinosa J, Pérez-Cuevas R: Higia y panacea en la salud y la sociedad. Los sistemas de salud, un producto de la evolución social. / Rev Med Inst Mex Seguro Soc 2005, 43:411-17.
  27. Abramson SB, Weaver AL: Current state of therapy for pain and inflammation. / Arthritis Res Ther 2005,7(suppl 4):S1-S6. CrossRef
  28. Bellamy N, Kean WF, Buchanan WW, Gerecz-Simon E, Campell J: Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC osteoarthritis index. / J Rheumatol 1992, 19:153.
  29. Ta LE, Dionne RA: Treatment of painful temporomandibular joints with a cycloxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. / Pain 2004, 111:13-1. CrossRef
  30. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, / et al.: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. / Mayo Clin Proc 1999, 74:1095-105. CrossRef
  31. Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, / et al.: Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. / J Int Med Res 2001, 29:467-79.
  32. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, / et al.: Patient preference for placebo, acetaminophen (paracetamol) of celecoxib efficacy studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. / Ann Rheum Dis 2004, 63:931-39. CrossRef
  33. Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS: Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double blind study vs. placebo and celecoxib. / Curr Med Res Opin 2005, 21:517-6. CrossRef
  34. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS: Efficacy and tolerability of lumiracoxib of osteoarthritis of knee: a 13 week, randomized, double-blind comparison with celecoxib and placebo. / Clin Ther 2005, 27:64-7. CrossRef
  35. Case JP, Baliunas AJ, Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. / Arch Intern Med 2003, 163:169-78. CrossRef
  36. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Elisen G, / et al.: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis? The CLASS study: a randomized controlled trial. / JAMA 2000, 284:1247-255. CrossRef
  37. Schnitzer TJ, Burnmester GR, Myster E, Hochberg MC, Doherty M, Ehrsam E, / et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. / Lancet 2004, 364:665-74. CrossRef
  38. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FWA, Schnitzer TJ, / et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. / Lancet 2004, 364:675-84. CrossRef
  39. Deeks JJ, Smith LA, Bradley M: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trial. / BMJ 2002, 325:629-26. CrossRef
  40. Zhang W, Jones A, Doherty M: Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? a meta-analysis of randomised controlled trials. / Ann Rheum Dis 2004, 63:901-07. CrossRef
  41. Bjordal JM, Ljunggren AL, Klovning A, Stordal L: Non-steroidal anti-inflammatory drugs, including cyclooxygenase 2 inhibitors in osteoarthritis knee pain: meta-analysis of randomised placebo controlled trial. / BMJ 2004, 329:1317-322. CrossRef
  42. Instituto Mexicano del Seguro Social. Secretaria General: Aviso: Costos unitarios de la atención médica. Diario Oficial de la Federación. Martes 9 de marzo de 2004. / Primera Sección106-07.
  43. Web Instituto Mexicano del Seguro Social [http://www.imss.gob.mx] 2004.
  44. Kristiansen IS, Kvien TK: Cost-effectiveness of replacing NSAIDs with coxibs; diclofenac and celecoxib in rheumatoid arthritis. / Expert Rev Pharmacoeconomic Outcomes Res 2002, 2:229-41. CrossRef
  45. Kamath CC, Kremers HM, Vanness DJ, O'Fallon WM, Cabanela RL, Gabriel SE: The Cost-Effectiveness of Acetaminophen, NSAIDs, and Selective COX-2 Inhibitors in the Treatment of Symptomatic Knee Osteoartritis. / Value Health 2003, 6:144-57. CrossRef
  46. Mould-Quevedo JF, Contreras I, Nevarez A, García-Contreras F, Constantino-Casas P, Gardu?o J: Cost-utility analysis for statins in Mexico. / Value Health 2005, 8:269.
  47. Zabinski RA, Burke TA, Jonson J, Lavoie F, Fitzsimon C, Tretiak R, / et al.: An economic model for determining the costs and consequences of using various treatment alternatives for management of arthritis in Canada. / Pharmacoeconomics 2001,19(Suppl):49-8. CrossRef
  48. Spiegel BMR, Targownik LE, Gareth S, Gralnek IM: The cost-effectiveness of cyclooxygenase-2 selective inhibitors in management of chronic arthritis. / Ann Intern Med 2003, 138:795-06.
  49. Maetzel A, Krahn M, Naglie G: The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. / Arthritis Rheum 2003, 49:283-92. CrossRef
  50. Singh G, Wu O, Langhorne P, Madhok R: Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. / Arthritis Res Ter 2006, 8:R153. CrossRef
  51. Dray A, Read SJ: Future targets to control osteoarthritis pain. / Arthritis Res Ter 2007, 9:212. CrossRef
  52. Moore RA, Derry S, Makinson GT, McQuay HJ: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. / Arthritis Res Ter 2005, 7:R644-R665. CrossRef
  53. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazierses B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Vebruggen G, Zimmerman-Gorska I, Dogados M: EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the stansing committee for international clinical studies including therapeutic trials (ESCISIT). / Ann Rheum Dis 2003, 62:1145-155. CrossRef
  54. Fitzgerald GA, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. / N Engl J Med 2001, 345:433-42. CrossRef
  55. Topol EJ: Failing the public health-rofecoxib. Merck and the FDA. / N Engl J Med 2004, 351:1707-709. CrossRef
  56. Marcus AJ, Brockman MJ, Pinsky DJ: COX inhibitors and thromboregulation. / N Engl J Med 2002, 347:1025-6. CrossRef
  57. Wright JM: The double-edged sword of COX-2 selective NSAIDs. / CMAJ 2002, 167:1131-137.
  58. Memorandum from David J, Graham MDMPH, Associate Director for Science, Office of Drug Safety to Paul Seligman, MD, MPH, Acting Director: Office of Drug Safety entitled, "Risk of Acute Myocardial Infarction and Sudden Cardiac Death in Patients Treated with COX-2 Selective and Non-Selective NSAIDs".
  59. Patterson MK, Castellsague J, Walker AM: Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. / Pharmacoepidemiol Drug Saf 2008, 17:982-88. CrossRef
  60. Arthritis Research Campaign [http://www.arc.org.uk/news/arthritistoday/126_4.asp]
  61. Haq I, Murphy E, Dacre J: Osteoarthritis. / Postgrad Med J 2003, 79:377-83. CrossRef
  62. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, / et al.: The effects of specific medical conditions of functional limitations of elders in the Farmingham study. / Am J Public Health 1994, 84:351-. CrossRef
  63. Vera-Bola?os MG: La teoría de la transición epidemiológica. / Documentos de Investigación El colegio mexiquense AC 1999.
  64. Cardiel MH, Rojas-Serrano J: Community based study to estimate prevalence, burden of illness and help seeking behaviour in rheumatic diseases in Mexico city. ACOPCORD study. / Clin Exp Rheumatol 2002, 20:617-24.
  65. Mejía-Aranguré JM, Bonilla M, Lorenzana R, Juárez-Oca?a S, de Reyes G, Pérez-Saldivar ML, / et al.: Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: Population-based data. / BMC Cancer 2005, 5:33. CrossRef
  66. Shleimann F: Combating disease and promoting health. / Global Forum Update on Research for Health 2006, 3:146-48.
  67. Cantor SB: Cost-effectiveness analysis, extended dominance, and ethics. / Med Decis Making 1994, 14:259-65. CrossRef
  
• 作者单位：Iris Contreras-Hernández (1)
  Joaquín F Mould-Quevedo (1)
  Rubén Torres-González (2)
  María Victoria Goycochea-Robles (3)
  Lizette Reyna Pacheco-Domínguez (1)
  Sergio Sánchez-García (4)
  Juan Manuel Mejía-Aranguré (5)
  Juan Gardu?o-Espinosa (1)
  
  1. Unidad de Investigación en Economía de la Salud, Instituto Mexicano del Seguro Social, Mexico, D.F, Mexico
  2. Hospital de Traumatología y Ortopedia: Unidad Médica de Alta Especialidad "Dr. Victorio de la Fuente Narváez", Instituto Mexicano del Seguro Social, Mexico, D.F, Mexico
  3. Hospital General Regional No. 1, Instituto Mexicano del Seguro Social, Mexico, D.F, Mexico
  4. Unidad de Investigación en Servicios de Salud, Envejecimiento, Instituto Mexicano del Seguro Social, Mexico, D.F, Mexico
  5. Unidad de Investigación en Epidemiología Clínica, UMAE Hospital de Pediatría, Instituto Mexicano del Seguro Social, Mexico, D.F, Mexico
  

文摘

Background Osteoarthritis (OA) is one of the main causes of disability worldwide, especially in persons >55 years of age. Currently, controversy remains about the best therapeutic alternative for this disease when evaluated from a cost-effectiveness viewpoint. For Social Security Institutions in developing countries, it is very important to assess what drugs may decrease the subsequent use of medical care resources, considering their adverse events that are known to have a significant increase in medical care costs of patients with OA. Three treatment alternatives were compared: celecoxib (200 mg twice daily), non-selective NSAIDs (naproxen, 500 mg twice daily; diclofenac, 100 mg twice daily; and piroxicam, 20 mg/day) and acetaminophen, 1000 mg twice daily. The aim of this study was to identify the most cost-effective first-choice pharmacological treatment for the control of joint pain secondary to OA in patients treated at the Instituto Mexicano del Seguro Social (IMSS). Methods A cost-effectiveness assessment was carried out. A systematic review of the literature was performed to obtain transition probabilities. In order to evaluate analysis robustness, one-way and probabilistic sensitivity analyses were conducted. Estimations were done for a 6-month period. Results Treatment demonstrating the best cost-effectiveness results [lowest cost-effectiveness ratio $17.5 pesos/patient ($1.75 USD)] was celecoxib. According to the one-way sensitivity analysis, celecoxib would need to markedly decrease its effectiveness in order for it to not be the optimal treatment option. In the probabilistic analysis, both in the construction of the acceptability curves and in the estimation of net economic benefits, the most cost-effective option was celecoxib. Conclusion From a Mexican institutional perspective and probably in other Social Security Institutions in similar developing countries, the most cost-effective option for treatment of knee and/or hip OA would be celecoxib.